External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

2022 ASCO Annual Meeting

June 03 - June 07

Chicago, USA / Virtual (Hybrid)

asco.org

Add to calendar

Medical Materials

Agenda

Coming soon

01:00 PM

Duration 12mins E450

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥2 prior therapies: pivotal Phase II expansion results

Dickinson M, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, Wu S-J, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Clark E, Humphrey K, Martin M

Haematology - Oncology | Non Hodgkin Lymphoma

Add to calendar

09:45 AM

Duration 12mins Arie Crown Theater

SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)

Rudin C, Liu S, Lu S, Soo R, Hong MH, Lee JS, Bryl M, Dumoulin D, Rittmeyer A, Chiu CH, Ozyilkan O, Navarro A, Novello S, Ozawa Y, Meng R, Hoang T, Lee A, Wen X, Huang M, Reck M

Oncology | Lung Cancer

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.